can tirzepatide cause cancer Could weight loss medication prevent breast recurrence? Risk of pancreatic cancer associated

Furthermore, Eli Lilly's reliance on GLP-1 drugs, which constitute over 60% of its revenue, raises concerns about portfolio concentration

This prolonged, supraphysiological stimulation results in greater glucose-lowering effects, more pronounced appetite suppression, and clinically significant weight loss that varies by medication and dose: approximately 5-8% with liraglutide 3 mg, 10-15% with semaglutide 2.4 mg, and 15-22% with tirzepatide at higher doses

That parent company carries a history that includes FDA scrutiny, executive fraud convictions, and regulatory violations spanning multiple years

Nrf2, nuclear factor erythroid 2related factor 2

10.3892/ol.2014.2358 15